AI Article Synopsis
- The HPV Serology Laboratory at the Frederick National Laboratory for Cancer Research is collaborating with the scientific community to standardize HPV serology assays, which are crucial for regulatory approvals of vaccines.
- A virtual meeting took place on June 29-30, 2021, to assess progress on this standardization initiative and address scientific gaps.
- Key topics discussed included assay standardization, calibration procedures, cut-off values, ongoing immunobridging trials, and challenges in standardizing HPV serology practices.
Article Abstract
The HPV Serology Laboratory in the Frederick National Laboratory for Cancer Research is working in partnership with the scientific community with the goal of standardizing and harmonizing current HPV serology assay platforms in response to the increasing number of immunobridging trials relying on serology data for approval of new vaccine dosing schedules and new formulations. A virtual meeting was held on June 29-30, 2021, to review the progress of the standardization initiative thus far and to bridge scientific gaps and outstanding questions. The main aims and outcomes of the meeting were to discuss: 1) standardization of assays and reagents; 2) International Standard calibration procedures; 3) assay cut-off values; 4) current immunobridging clinical trials; and 5) gaps and challenges in standardization of HPV serology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216077 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2023.01.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!